Cinnamic Acid | 621-82-9
$23.00 - $80.00
All products have special prices for bulk purchase, please contact for more details if required.
Cat. No.: CNAC-0.2 (for 10mM×0.2ml)
Cat. No.: CNAC-25 (for 25mg)
Cat. No.: CNAC-100 (for 100mg)
Description
Cinnamic acid shows promise in cancer intervention, exhibiting IC50 values ranging from 1 to 4.5 mM in glioblastoma, melanoma, prostate, and lung carcinoma cells.
Basic Information
- Aliases: 3-Phenylacrylic acid; β-Phenylacrylic acid; Myricitrine; Phenylacrylic acid; Cinnamylic acid; Isocinnamic acid
- Source: Liquidambar orientalis Mill.
- Compound type: Phenylpropanoids > Phenylpropanoic acids
- Chemical Formula: C9H8O2
- Molecular Weight: 148.16
- CAS Number: 621-82-9
- Purity: 98%, HPLC
- Solvent/Solubility: Ethanol: ≥ 50 mg/ml (337.47 mM); DMSO: 50 mg/ml (337.47 mM)
- Solution Preparation: Add 2mg to 1.35ml of DMSO, or add 1.48mg to 1ml of DMSO, to prepare a 10mM solution.
Signaling Pathway
-
In Vitro Study
Treatment with cinnamic acid (CINN) on various tumor cells of epithelial and neuroectodermal origin leads to dose-dependent growth inhibition following a 3-day exposure. The inhibitory concentrations causing a 50% reduction in tumor-cell proliferation (IC50) range from 1.2 to 4.5 mM. Notably, FS4 cells require 20 mM cinnamic acid to achieve an IC50, which is 5 to 20 times higher than that for other tumor cells.
In addition to its role in inhibiting tumor-cell proliferation, cinnamic acid induces morphological changes consistent with melanocyte differentiation. Within 5 days of treatment with 5 mM cinnamic acid, melanoma 1011 cells display enlargement, markedly increased cytoplasm-to-nuclear ratio, a well-organized cytoskeleton, long dendritic processes, and heightened melanotic activity.
The impact of cinnamic acid on the invasive capacity of treated melanoma 1011, A375(M), and SKMEL28 cells is evaluated using an in vitro invasion assay with modified Boyden chambers featuring matrigel-coated filters. After continuous treatment with cinnamic acid for 3 days, a dose-dependent reduction in invasive capacity is observed across the three tested tumor lines. Treatment with 5 mM cinnamic acid results in a substantial decrease in invasiveness, ranging from 75% to 95%.
In Vivo Study
N/A
Clinical Trial
N/A
Storage
Store at -20°C for at least one year. The solid powder is stable at 4°C for at least one month. If dissolved in a non-DMSO solvent, it is recommended to aliquot and store at -80°C for up to six months.
Precautions
- This product may have a certain degree of toxicity to the human body. Please take appropriate precautions to avoid direct contact with the body or inhalation.
- This product is for scientific research use only by professionals and is not intended for clinical diagnosis or treatment, food, or pharmaceutical purposes. It should not be stored in ordinary residential areas.
- For your safety and health, please wear laboratory attire and disposable gloves while handling.
Only for research and not intended for treatment of humans or animals
Journals Using SBS Genetech Products Universities Using SBS Genetech Products
SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory
